L'intérêt à découvert pour Rocket Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Rocket Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock, Rapport sur les intérêts à découvert

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 67.86 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $583.00 million which missed the analyst consensus estimate of $627.84 million by 7.14 percent. This is a 11.80 percent decrease over sales of $661.00 million the same period last year.

Earnings

Earnings Misses

News

Intl Game Tech Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $583.00M Miss $627.84M Estimate

Needham analyst Ryan Koontz reiterates Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and maintains $28 price target.

Price Target

Reiteration

Analyst Ratings

RKLB

Needham Reiterates Buy on Rocket Lab USA, Maintains $28 Price Target

CNCK

Coincheck Group Q1 Sales $764.00M Up From $676.00M YoY, Net Profit $4.3M Down From $13M YoY

DA Davidson analyst Rudy Kessinger downgrades Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowers the price target from $29 to $21.

Downgrades

DA Davidson Downgrades Rapid7 to Underperform, Lowers Price Target to $21

Compass Point analyst Merrill Ross downgrades NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and lowers the price target from $50 to $42.5.

NXRT

Compass Point Downgrades NexPoint Residential to Neutral, Lowers Price Target to $42.5

JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 48.72 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $41.49 billion which beat the analyst consensus estimate of $40.20 billion by 3.21 percent. This is a 15.20 percent increase over sales of $36.02 billion the same period last year.

Earnings Beats

CORRECTION: JD.com Q1 Adj. EPADS $1.16 Beats $1.05 Estimate, Sales $41.49B Beat $40.20B Estimate

Compass Point analyst Merrill Ross downgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announces $22 price target.

Compass Point Downgrades Independence Realty Trust to Neutral, Announces $22 Price Target

China firmly rejected responsibility for the U.S. fentanyl crisis on Tuesday, calling Washington&#8217;s punitive tariffs unreasonable even as broader trade tensions between the world&#8217;s two largest economies show signs of easing.
What Happened: &#8220;The responsibility of tackling the fentanyl issue in the United States lies within the U.S. itself,&#8221; Chinese foreign ministry spokesperson Lin Jian stated during a regular press briefing, according to Reuters. Lin was responding to questions about whether fentanyl would be discussed in future trade negotiations.
The comments come just days after both nations pledged to significantly reduce tariffs following productive talks in Switzerland. Despite this progress, the U.S. maintained its 20% tariffs specifically tied to fentanyl, claiming Beijing hasn&#8217;t done enough to stem the flow of precursor chemicals used to manufacture the deadly opioid.
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45368550/apple-may-up-its-numbers-amid-china-tariff-truce-trump-talks-500-billion-us-investment-after-tim-cook-call">Apple May &#8216;Up Its Numbers&#8217; Amid China Tariff Truce: Trump Talks $500 Billion US Investment After Tim Cook Call</a>
Why It Matters: President Donald Trump&#8216;s Monday executive order decreased general <a href="https://www.benzinga.com/government/regulations/25/05/45368852/trump-lowers-de-minimis-tariff-on-chinese-imports-from-120-to-54-pauses-200-postal-fee-amid-90-day-trade-shift">Chinese import tariffs to 10% for a 90-day negotiation period</a> and reduced the de minimis rate on low-value imports from 120% to 54%, effective Tuesday. However, the fentanyl-related tariffs remained intact.
Analysts suggest the fentanyl issue could become a <a href="https://www.benzinga.com/news/global/25/05/45188171/china-pushes-for-special-envoys-as-direct-deal-with-trump-deemed-risky-plans-fentanyl-concessions-as-negotiating-leverage-report">strategic bargaining chip in upcoming negotiations</a>. &#8220;Beijing is hoping to use fentanyl cooperation as either a catalyst for U.S.-China trade talks or a bargaining chip in a future round of negotiations,&#8221; Jeremy Chan of Eurasia Group said.
Morgan Stanley economists project that continued negotiations could potentially lower overall tariffs on Chinese imports to 34% by the end of 2025, which would indicate the eventual elimination of the 20% fentanyl-specific tariff if sufficient progress is made on addressing U.S. concerns.
Image Via Shutterstock 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45369152/mcdonalds-launches-massive-summer-hiring-drive-for-375000-workers-amid-us-expansion-plans-and-slumping-sales">McDonald&#8217;s Launches Massive Summer Hiring Drive For 375,000 Workers Amid US Expansion Plans And Slumping Sales</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Economics

China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions

Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) affirms FY2025 FFO guidance from $0.57-$0.61 to $0.57-$0.61 vs $0.54 analyst estimate. Affirms FY2025 sales outlook from $183.39 million-$188.17 million to $183.39 million-$188.17 million vs $186.60 million estimate.

Guidance

SOHO

Sotherly Hotels Affirms FY2025 FFO Guidance of $0.57-$0.61 vs $0.54 Est; Affirms FY2025 Sales Guidance of $183.39M-$188.17M vs $186.60M Est

The shares of Avic Chengdu Aircraft, known for manufacturing fighter jets like the JF-17 Thunder and the J-10C Vigorous Dragon, saw a 41.08% surge over the past five days since the commencement of the<a href="https://www.benzinga.com/news/global/25/05/45335338/trump-makes-india-pakistan-ceasefire-declaration-in-casual-manner-thank-you-for-your-attention-to-this-matter"> India-Pakistan conflict.</a>
What Happened: This rise was amid growing tensions between India and Pakistan following New Delhi&#8217;s recent military actions to avenge the alleged killings of tourists by <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Pakistani terrorists</a> in Pahalgam, Kashmir.
On Friday, U.S. officials confirmed that a Chinese-made J-10 fighter jet fired air-to-air missiles at Indian aircraft, reportedly resulting in the downing of a French-built Rafale jet. The Pakistani Defense Minister, Khawaja Muhammad Asif, also said that the Chinese-made J-10 was used to shoot down three of India's newly acquired Rafale jets. 
Notably, the Indian military has not issued a clear response to the claim. "We are in a combat scenario and losses are a part of it. All our pilots are back home," stated Air Marshal A.K. Bharti on Sunday.
However, after a steep rise, the Avic Chengdu stock tumbled over 7% on Tuesday, possibly in response to a statement from Indian Prime Minister Narendra Modi. Modi on Monday announced the successful completion of Operation Sindoor. This statement triggered a massive selloff in Chinese defense stocks.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally" target="_blank" rel="noreferrer noopener">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally &#8211; Benzinga</a>
Why It Matters: If confirmed, this would be the first combat success of the J-10 family since the original J-10 was unveiled 27 years ago. Pakistan, a long-standing ally of China, is the only foreign country operating the advanced J-10C, with a fleet of 20. This incident also marked the first reported loss of a Rafale fighter jet in combat, according <a href="https://www.scmp.com/news/china/military/article/3309781/j-10cs-deepseek-moment-beijing-muted-china-cheers-fighter-jet-combat-reports">to</a> the South China Morning Post.
While Chinese citizens praised the J-10C fighter jet&#8217;s role in the India-Pakistan conflict as a milestone for China&#8217;s defense industry, Beijing maintained a cautious stance. Analysts attributed this to geopolitical sensitivities and military prudence. The only official response from Beijing urged both countries to show restraint and avoid escalating tensions, reported the publication. 
Meanwhile, this incident had sent <a href="https://www.benzinga.com/25/05/45342121/chinese-made-pakistani-jet-downs-two-indian-aircraft">shockwaves across defense circles </a>and rattled investors, causing shares of French manufacturer Dassault Aviation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DUAVF#OTC">DUAVF</a>) to plunge.
President Donald Trump announced on Saturday a U.S.-<a href="https://www.benzinga.com/markets/equities/25/05/45336288/india-pakistan-ceasefire-teeters-as-blasts-shatter-calm-in-kashmir">brokered ceasefire </a>between India and Pakistan.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45368511/china-to-us-goods-shipment-jump-after-90-day-tariff-postponement-a-big-backlog-is-looming" target="_blank" rel="noreferrer noopener">China To US Goods Shipment Jump After 90-Day Tariff Postponement: &#8216;A Big Backlog Is Looming&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Markets

DUAVF

This Chinese Defense Stock Soared Over 41% In 5 Days: What's Going On?

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) affirms FY2025 sales outlook from $75.00 million-$90.00 million to $75.00 million-$90.00 million vs $82.49 million estimate.

YMAB

Y-mAbs Therapeutics Affirms FY2025 Sales Guidance of $75.00M-$90.00M vs $82.49M Est

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) sees Q2 sales of $17.000 million-$19.000 million vs $19.61 million analyst estimate.

Y-mAbs Therapeutics Sees Q2 Sales $17.000M-$19.000M vs $19.61M Est

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.64 by 1.56 percent. This is a 1725 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $4.84 billion which missed the analyst consensus estimate of $4.89 billion by 1.03 percent. This is a 29.65 percent increase over sales of $3.73 billion the same period last year.

Sea Q1 EPS $0.65 Beats $0.64 Estimate, Sales $4.84B Miss $4.89B Estimate

Needham analyst Joseph Stringer maintains Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and lowers the price target from $16 to $11.

ANNX

Needham Maintains Buy on Annexon, Lowers Price Target to $11

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 40 percent. This is a 20 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $20.90 million which beat the analyst consensus estimate of $19.61 million by 6.62 percent. This is a 4.88 percent increase over sales of $19.93 million the same period last year.

Y-mAbs Therapeutics Q1 EPS $(0.12) Beats $(0.20) Estimate, Sales $20.90M Beat $19.61M Estimate

Teleflex Reports Titan SGS Stapler Associated With Lower Post-Operative GERD Rates In 7-Year Retrospective Study Of Robotic Sleeve Gastrectomy Patients

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty's decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company's Board of Directors and Witty will serve as a senior adviser to Hemsley.
Additionally, the company suspended its 2025 outlook as care activity continued to accelerate while also broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
The company expects to return to growth in 2026.

Management

UnitedHealth CEO Andrew Witty Steps Down For Personal Reasons; Chair Stephen Hemsley Takes Over As New Chief, Expects To Reurn To Growth In 2026

Honda Motor Co FY25 GAAP EPS ¥178.93 Down From ¥225.88 YoY, Sales ¥21.688T Up From ¥20.428T YoY

First product validated at the VALOR lab's new RF-shielded anechoic chamber
CHANDLER, Ariz., May 13, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425153-1&amp;h=1206137132&amp;u=https%3A%2F%2Fwww.viavisolutions.com%2F&amp;a=VIAVI+Solutions+Inc.">VIAVI Solutions Inc.</a> (VIAVI) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) today announced that <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425153-1&amp;h=3385565414&amp;u=https%3A%2F%2Fmetanoia-comm.com%2F&amp;a=Metanoia+Communications+Inc.">Metanoia Communications Inc.</a>'s JURA&nbsp;Open Radio Unit (O-RU) has successfully completed end-to-end over-the-air (OTA) validation at the VIAVI Automated Lab-as-a-Service (VALOR&#x2122;). It is the first product to be validated at the lab's new RF-shielded anechoic chamber to ensure compliance with O-RAN and 3GPP specifications.

VIAV

VIAVI Solutions Says Metanoia Communications' JURA Open Radio Unit Completes End-To-End Over-The-Air Validation At VIAVI Automated Lab-As-A-Service

Large Cap

Health Care

General

UnitedHealth Appoints Stephen Hemsley As Its CEO, Effective Immediately, Following Andrew Witty's Decision To Step Down As CEO For Personal Reasons. Hemsley, Who Served As Company CEO From 2006-2017, Will Remain Chairman Of The Company's Board Of Directors And Witty Will Serve As A Senior Adviser To Hemsley

Press Releases

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Comments

Rocket Pharmaceuticals

Intérêt court

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL